Payment integrity
Recoveries & appeals
Centene · payment integrity
Performance
Recovery and audit yield
The current period against the four before it. Every figure is computed from the claims in the batch.
Overpayment identified per period
Hit rate by selection method
Drug and biologic spend
1 of 2 · 50%
Advanced imaging review
1 of 3 · 33%
DRG severity tier review
2 of 4 · 50%
E/M level distribution
1 of 3 · 33%
Cost threshold
0 of 2 · 0%
Bundling and duplicate rules
2 of 5 · 40%
Random sample (control)
0 of 6 · 0%
The random control sample is the line the others are measured against. Every finding in this batch came from a targeted criterion; the control group found nothing, which is what makes the targeted rates mean something.
Yield by clinical and cost class
| Class | Claims | Share of batch | Paid | Findings | Identified |
|---|---|---|---|---|---|
|
Advanced imaging
MRI, CT, PET and nuclear studies
|
3 | 12% | $762.87 | 1 | $254.18 |
|
Drug and biologic
Physician-administered drugs on the medical benefit
|
2 | 8% | $11,153.61 | 1 | $1,344.96 |
|
Inpatient admissions
Institutional claims priced by DRG
|
8 | 32% | $70,167.31 | 2 | $9,528.92 |
|
Above the cost threshold
Paid above $500.00
|
12 | 48% | $86,113.80 | 4 | $14,963.11 |
|
Up-coded
Billed at a higher level, severity or unit count than the record supports
|
5 | 20% | — | 5 | $15,030.82 |
A claim can sit in more than one class, so the rows overlap and do not sum to the batch. Every figure is computed from the claims.
Auditor throughput
| Team | Claims reviewed | Findings confirmed | Overturned on dispute | Avg review time |
|---|---|---|---|---|
| Professional claims audit | 6 | 2 | 0 of 4 | 18m 40s |
| Facility audit | 4 | 1 | 1 of 3 | 26m 10s |
| Lab and ancillary | 2 | 0 | 0 of 1 | 9m 25s |